Noxopharm Past Earnings Performance
Past criteria checks 0/6
Noxopharm's earnings have been declining at an average annual rate of -14.4%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 5.2% per year.
Key information
-14.4%
Earnings growth rate
13.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 5.2% |
| Return on equity | -184.4% |
| Net Margin | -312.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Noxopharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4 | -12 | 5 | 0 |
| 30 Sep 23 | 5 | -14 | 5 | 0 |
| 30 Jun 23 | 6 | -15 | 6 | 0 |
| 31 Mar 23 | 6 | -15 | 6 | 0 |
| 31 Dec 22 | 7 | -15 | 7 | 0 |
| 30 Sep 22 | 6 | -17 | 7 | 0 |
| 30 Jun 22 | 5 | -19 | 7 | 0 |
| 31 Mar 22 | 6 | -15 | 7 | 0 |
| 31 Dec 21 | 6 | -11 | 6 | 0 |
| 30 Sep 21 | 6 | -10 | 7 | 0 |
| 30 Jun 21 | 6 | -9 | 7 | 0 |
| 31 Mar 21 | 6 | -5 | 7 | 0 |
| 31 Dec 20 | 6 | 0 | 7 | 0 |
| 30 Sep 20 | 7 | 0 | 8 | 0 |
| 30 Jun 20 | 8 | 0 | 8 | 0 |
| 31 Mar 20 | 6 | -7 | 9 | 2 |
| 31 Dec 19 | 4 | -15 | 10 | 4 |
| 30 Sep 19 | 4 | -13 | 10 | 5 |
| 30 Jun 19 | 4 | -11 | 9 | 7 |
| 31 Mar 19 | 4 | -11 | 9 | 6 |
| 31 Dec 18 | 3 | -10 | 8 | 5 |
| 30 Sep 18 | 2 | -14 | 7 | 4 |
| 30 Jun 18 | 1 | -18 | 6 | 4 |
| 31 Mar 18 | 1 | -16 | 5 | 3 |
| 31 Dec 17 | 1 | -14 | 4 | 3 |
| 30 Sep 17 | 1 | -8 | 3 | 2 |
| 30 Jun 17 | 0 | -3 | 2 | 1 |
| 31 Mar 17 | 0 | -3 | 2 | 1 |
Quality Earnings: NOXO.F is currently unprofitable.
Growing Profit Margin: NOXO.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NOXO.F is unprofitable, and losses have increased over the past 5 years at a rate of 14.4% per year.
Accelerating Growth: Unable to compare NOXO.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NOXO.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: NOXO.F has a negative Return on Equity (-184.44%), as it is currently unprofitable.